The best guess approach to phase I trial design

Journal of Clinical Oncology

Volumn 24, Issue 1, 2006, Pages 206-208

  Rosa, Daniela D ^a   Harris, John ^a   Jayson, Gordon C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CASE REPORT; CLINICAL TRIAL; COHORT ANALYSIS; DRUG INDUSTRY; DRUG TARGETING; FEMALE; HUMAN; MAXIMUM TOLERATED DOSE; OVARY CANCER; PATIENT INFORMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; METHODOLOGY; MIDDLE AGED; OVARY TUMOR;

CLINICAL TRIALS, PHASE I; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RESEARCH DESIGN;

EID: 33644841960     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.02.4299     Document Type: Article

References (35)

1. Kurzrock R, Benjamin RS: Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 352:930-932, 2005
2. Horng S, Emanuel EJ, Wilfond B, et al: Descriptions of benefits and risks in consent forms for phase I oncology trials. N Engl J Med 347:2134-2140, 2002
3. Nottage M, Siu L: Principles of clinical trial design. J Clin Oncol 20:42s-46s, 2002
4. Miller M: Phase I cancer trials: A crucible of competing priorities. Int Anesthesiol Clin 39:13-33, 2001
5. Meropol NJ, Weinfurt KP, Burnett CB, et al: Perceptions of patients and physicians regarding phase I cancer clinical trials: Implications for physician-patient communication. J Clin Oncol 21:2589-2596, 2003
6. Conaway MR, Dunbar S, Peddada SD: Designs for single- or multiple-agent phase I trials. Biometrics 60:661-669, 2004
7. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
8. Eisenhauer EA, O'Dwyer PJ, Christian M, et al: Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684-692, 2000
9. Newell DR, Silvester J, McDowell C, et al: The Cancer Res UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies. Eur J Cancer 40:899-906, 2004
10. Bolognese JAA: Monte Carlo comparison of three up-and down designs for dose ranging. Control Clin Trials 4:187-196, 1983
11. Agrawal M, Emanuel EJ: Ethics of phase I oncology studies. JAMA 290:1075-1082, 2003
12. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005
13. Saltz LB, Meropol NJ, Loehrer PJ, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
14. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
15. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF specific antibody bevacizumab has antivascular effects in human rectal carcinoma. Nat Med 10:145-147, 2004
16. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab with CHOP chemotherapy alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
17. Quigley J, Chevret S: Methods for dose-finding studies in cancer clinical trials: A review and results of a Monte Carlo study. Stat Med 10:1647-1664, 1991
18. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
19. Storer BE: Design and analysis of phase I clinical trials. Biometrics 45:925-937, 1989
20. Simon R, Freidlin B, Rubinstein L, et al: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138-1147, 1997
21. Grem JL, Morrison G, Guo XD, et al: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 23:1885-1893, 2005
22. Goetz MP, Toft D, Reid J, et al: Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 23:1078-1087, 2005
23. Wadler S, Makower D, Clairmont C, et al: Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2- carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 22:1553-1563, 2004
24. Matsumura Y, Hamaguchi T, Ura T, et al: Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91:1775-1781, 2004
25. Syed S, Takimoto C, Hidalgo M, et al: A phase I and pharmacokinetic study of col-3 (metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 10:6512-6521, 2004
26. Anderson HL, Yap JT, Miller MP, et al: Phase I and pharmacokinetic study of Bibx 1382 Bs: An epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. J Clin Oncol 21:2823-2830, 2003
27. Gadgeel SM, Boinpally RR, Heilbrun LK, et al: A phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a phase I accelerated titration "2B" design. Invest New Drugs 21:63-74, 2003
28. Plummer R, Ghielmini M, Calvert P, et al: Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies. Clin Cancer Res 8:2788-2797, 2002
29. Dittrich C, Greim G, Borner M, et al: Phase 1 and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 38:1072-1080, 2002
30. Goh BC, Ratain MJ, Bertucci D, et al: Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol 19:1476-1484, 2001
31. Houston JB: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479, 1994
32. Lave T, Coassolo P, Reigner B: Prediction of hepatic metabolic clearance based on interspecies allometric techniques and in vitro -in vivo correlations. Clin Pharmacokinet 36:211-231, 1999
33. Christian MC, Korn EL: The limited precision of phase I trials. J Natl Cancer Inst 86:1662-1663, 1994
34. Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33-48, 1990
35. Quigley J: Estimating the probability of toxicity at the recommended doses following a phase I clinical trial in cancer. Biometrics 48:853-862, 1992